Intravitreal injection of cell membrane-coated nanoparticles for retinoblastoma treatment

  • J Control Release. 2025 Jun 6:385:113939. doi: 10.1016/j.jconrel.2025.113939.
Yichi Zhang  1 ,  Kaiqi Long  1 ,  Ka Yi Lee  2 ,  Jia Li  1 ,  Shuting Xu  1 ,  Kang Chen  2 ,  Xi Chen  1 ,  Qingyi Dai  3 ,  Yifan Lin  4 ,  Changyou Zhan  5 ,  Weiping Wang  6
Affiliations
  • 1. State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China.
  • 2. State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China.
  • 3. State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China; Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China.
  • 4. Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China.
  • 5. Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, China.
  • 6. State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China; Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China. Electronic address: [email protected].
PMID: 40484284 DOI: 10.1016/j.jconrel.2025.113939
Abstract

Chemotherapy is a widely adopted treatment for malignant intraocular tumors such as retinoblastoma. However, achieving high delivery efficiency remains challenging due to rapid clearance and lack of targeting specificity. Cancer cell membrane-coated nanoparticles have been extensively reported to exhibit specific affinity to homotypic Cancer cells. Here we designed poly (lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles coated with the plasma membrane of WERI-Rb-1 cells, derived from human retinoblastoma. These nanoparticles showed remarkable affinity to WERI-Rb-1 cells in vitro. Loaded with the FDA-approved chemotherapy drug etoposide, the nanoparticles exhibited excellent antitumor efficacy and excellent biosafety following a single-dose intravitreal injection in vivo. Overall, this work presents a simple yet effective strategy for the treatment of retinoblastoma.

Keywords
Cell membrane-coated nanoparticles; Homotyic targeting; Intraocular drug delivery; Intravitreal injection; Retinoblastoma.
Products
Inhibitors & Agonists
Other Products